Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/203527/000020352720000008/var-20200103.htm
April 2021
April 2021
March 2021
March 2021
January 2021
November 2020
November 2020
October 2020
October 2020
October 2020
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/203527/000020352720000008/var-20200103.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Varian Medical Systems Inc.
Varian Medical Systems Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More
Cash, Cash Equivalents, and Restricted Cash The following table summarizes our cash, cash equivalents, and restricted cash: The increase in cash, cash equivalents, and restricted cash in the three months ended January 3, 2020 was primarily due to $132.0 million in net borrowings from our credit facility, $112.6 million of cash provided by operating activities, $19.7 million in proceeds from the issuance of common stock to employees, and $9.2 million in proceeds from the sale of an equity investment, partially offset by $43.8 million used for the repurchase of shares of VMS common stock, $22.6 million used for purchases of property, plant, and equipment, and $3.6 million used for tax withholdings on vesting of equity awards.
Oncology Systems service gross margin percentage increased in the three months ended January 3, 2020, compared to the year-ago period, primarily due to an increase in service revenues.
Actual results and the outcome or timing of certain events may differ significantly from those projected in these forward-looking statements or management's current expectations due to the factors cited in this "Management's Discussion and Analysis of Financial Condition and Results of Operations" ("MD&A"), the Risk Factors listed under Part II, Item 1A of this Quarterly Report on Form 10-Q, and other factors described from time to time in our other filings with the Securities and Exchange Commission ("SEC"), or other reasons.
This discussion and analysis of our financial condition and results of operations is based upon and should be read in conjunction with the Condensed Consolidated Financial Statements and the Notes included elsewhere in this Quarterly Report on Form 10-Q and the Consolidated Financial Statements, the Notes to the Consolidated Financial Statements and the related Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended September 27, 2019 (the "2019 Annual Report"), as well as the information contained under Part I, Item 1A "Risk Factors" of the 2019 Annual Report and Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q , and other information provided from time to time in our other filings with the SEC.
Approximately half of Oncology Systems gross orders and revenues come from international markets, within which certain emerging markets typically can have lower gross margins and longer installation cycles since many of these purchases are for new sites where treatment vaults need to be constructed.
Our critical accounting policies that...Read more
We have also been investing...Read more
In addition, government programs that...Read more
While we believe that improved...Read more
Other income, net, decreased in...Read more
Total service revenues increased in...Read more
?Inventory increasing $44.9 million primarily...Read more
Overall, we believe the global...Read more
Except for losses related to...Read more
We expect that fluctuations of...Read more
Our long-term growth and value...Read more
We have entered into indemnification...Read more
Days Sales Outstanding Our Oncology...Read more
In the three months ended...Read more
Oncology Systems service revenues, which...Read more
Other Income, Net Interest income...Read more
Gross Margin n/m - not...Read more
Our primary goal in the...Read more
Stock repurchases may be made...Read more
Oncology Systems gross orders are...Read more
Americas Oncology Systems revenues increased...Read more
EMEA Oncology Systems revenues increased...Read more
New orders are recorded for...Read more
Credit markets for proton therapy...Read more
Oncology Systems Revenues Oncology Systems...Read more
Forward-Looking Statements This Quarterly Report...Read more
?Deferred revenues increasing $57.4 million...Read more
Borrowings under our credit facilities...Read more
Although proton therapy has been...Read more
By making forward-looking statements, we...Read more
Reimbursement rates in the United...Read more
41 Diluted Net Earnings Per...Read more
The trailing 12 months' growth...Read more
As of January 3, 2020,...Read more
35 Currency fluctuations had approximately...Read more
36 We are investing resources...Read more
Acquisition-related expenses increased in the...Read more
In our view, the fundamental...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Varian Medical Systems Inc provided additional information to their SEC Filing as exhibits
Ticker: VAR
CIK: 203527
Form Type: 10-Q Quarterly Report
Accession Number: 0000203527-20-000008
Submitted to the SEC: Tue Feb 11 2020 4:58:54 PM EST
Accepted by the SEC: Tue Feb 11 2020
Period: Friday, January 3, 2020
Industry: Electromedical And Electrotherapeutic Apparatus